Janssen's Amivantamab, which is promoting joint development with Yuhan's non-small cell lung cancer treatment Leclaza, has been newly designated as an orphan drug.

The MFDS announced that it will newly designate five drugs, including Amivantamab, as orphan drugs, and announce additional target diseases for three drugs, including 5-Aminolevulinic acid HCl.

Orphan drugs are used for the purpose of diagnosing or treating rare diseases. It is a drug that has been designated by the Minister of Food and Drug Safety with no alternative drugs or with improved safety or efficacy than alternative drugs.

Amivantamab has been designated as a treatment for non-small cell lung ca